104 related articles for article (PubMed ID: 21280035)
1. Endometrial cancer associated with various forms of postmenopausal hormone therapy: a case control study.
Jaakkola S; Lyytinen HK; Dyba T; Ylikorkala O; Pukkala E
Int J Cancer; 2011 Apr; 128(7):1644-51. PubMed ID: 21280035
[TBL] [Abstract][Full Text] [Related]
2. A case-control study on hormone therapy as a risk factor for breast cancer in Finland: Intrauterine system carries a risk as well.
Lyytinen HK; Dyba T; Ylikorkala O; Pukkala EI
Int J Cancer; 2010 Jan; 126(2):483-9. PubMed ID: 19588504
[TBL] [Abstract][Full Text] [Related]
3. Effect of various forms of postmenopausal hormone therapy on the risk of ovarian cancer--a population-based case control study from Finland.
Koskela-Niska V; Pukkala E; Lyytinen H; Ylikorkala O; Dyba T
Int J Cancer; 2013 Oct; 133(7):1680-8. PubMed ID: 23526244
[TBL] [Abstract][Full Text] [Related]
4. Postmenopausal hormone therapy-also use of estradiol plus levonorgestrel-intrauterine system is associated with an increased risk of primary fallopian tube carcinoma.
Koskela-Niska V; Pukkala E; Lyytinen H; Ylikorkala O; Dyba T
Int J Cancer; 2015 Oct; 137(8):1947-52. PubMed ID: 25846583
[TBL] [Abstract][Full Text] [Related]
5. Ovarian cancer risk in postmenopausal women using estradiol-progestin therapy - a nationwide study.
Koskela-Niska V; Lyytinen H; Riska A; Pukkala E; Ylikorkala O
Climacteric; 2013 Feb; 16(1):48-53. PubMed ID: 22640598
[TBL] [Abstract][Full Text] [Related]
6. A 5-year study on the effect of hormone therapy, tibolone and raloxifene on vaginal bleeding and endometrial thickness.
Christodoulakos GE; Botsis DS; Lambrinoudaki IV; Papagianni VD; Panoulis CP; Creatsa MG; Alexandrou AP; Augoulea AD; Dendrinos SG; Creatsas GC
Maturitas; 2006 Mar; 53(4):413-23. PubMed ID: 16140483
[TBL] [Abstract][Full Text] [Related]
7. Primary fallopian tube carcinoma risk in users of postmenopausal hormone therapy in Finland.
Koskela-Niska V; Riska A; Lyytinen H; Pukkala E; Ylikorkala O
Gynecol Oncol; 2012 Aug; 126(2):241-4. PubMed ID: 22561401
[TBL] [Abstract][Full Text] [Related]
8. Do the dose or route of administration of norethisterone acetate as a part of hormone therapy play a role in risk of breast cancer: national-wide case-control study from Finland.
Lyytinen H; Dyba T; Pukkala E; Ylikorkala O
Int J Cancer; 2010 Jul; 127(1):185-9. PubMed ID: 19859914
[TBL] [Abstract][Full Text] [Related]
9. Endometrial carcinoma risks among menopausal estrogen plus progestin and unopposed estrogen users in a cohort of postmenopausal women.
Lacey JV; Brinton LA; Lubin JH; Sherman ME; Schatzkin A; Schairer C
Cancer Epidemiol Biomarkers Prev; 2005 Jul; 14(7):1724-31. PubMed ID: 16030108
[TBL] [Abstract][Full Text] [Related]
10. Postmenopausal estradiol-progestagen therapy and risk for uterine cervical cancer.
Jaakkola S; Pukkala E; K Lyytinen H; Ylikorkala O
Int J Cancer; 2012 Aug; 131(4):E537-43. PubMed ID: 22024969
[TBL] [Abstract][Full Text] [Related]
11. Endometrial cancer in postmenopausal women using estradiol-progestin therapy.
Jaakkola S; Lyytinen H; Pukkala E; Ylikorkala O
Obstet Gynecol; 2009 Dec; 114(6):1197-1204. PubMed ID: 19935019
[TBL] [Abstract][Full Text] [Related]
12. Cardiac Death Risk in Relation to the Age at Initiation or the Progestin Component of Hormone Therapies.
Savolainen-Peltonen H; Tuomikoski P; Korhonen P; Hoti F; Vattulainen P; Gissler M; Ylikorkala O; Mikkola TS
J Clin Endocrinol Metab; 2016 Jul; 101(7):2794-801. PubMed ID: 27172432
[TBL] [Abstract][Full Text] [Related]
13. Long-term postmenopausal hormone therapy and endometrial cancer.
Razavi P; Pike MC; Horn-Ross PL; Templeman C; Bernstein L; Ursin G
Cancer Epidemiol Biomarkers Prev; 2010 Feb; 19(2):475-83. PubMed ID: 20086105
[TBL] [Abstract][Full Text] [Related]
14. A nationwide cohort study on the incidence of meningioma in women using postmenopausal hormone therapy in Finland.
Korhonen K; Auvinen A; Lyytinen H; Ylikorkala O; Pukkala E
Am J Epidemiol; 2012 Feb; 175(4):309-14. PubMed ID: 22287638
[TBL] [Abstract][Full Text] [Related]
15. Continuous combined parenteral estrogen substitution and intrauterine progestogen delivery: the ideal HST combination?
Wildemeersch D; Janssens D; Weyers S
Maturitas; 2005 Jun; 51(2):207-14. PubMed ID: 15917162
[TBL] [Abstract][Full Text] [Related]
16. Estrogen-progestin replacement therapy and endometrial cancer.
Pike MC; Peters RK; Cozen W; Probst-Hensch NM; Felix JC; Wan PC; Mack TM
J Natl Cancer Inst; 1997 Aug; 89(15):1110-6. PubMed ID: 9262248
[TBL] [Abstract][Full Text] [Related]
17. Long-term use of postmenopausal estrogen and progestin hormone therapies and the risk of endometrial cancer.
Doherty JA; Cushing-Haugen KL; Saltzman BS; Voigt LF; Hill DA; Beresford SA; Chen C; Weiss NS
Am J Obstet Gynecol; 2007 Aug; 197(2):139.e1-7. PubMed ID: 17689625
[TBL] [Abstract][Full Text] [Related]
18. Risk of endometrial cancer following estrogen replacement with and without progestins.
Weiderpass E; Adami HO; Baron JA; Magnusson C; Bergström R; Lindgren A; Correia N; Persson I
J Natl Cancer Inst; 1999 Jul; 91(13):1131-7. PubMed ID: 10393721
[TBL] [Abstract][Full Text] [Related]
19. Case-control study of postmenopausal hormone replacement therapy and endometrial cancer.
Strom BL; Schinnar R; Weber AL; Bunin G; Berlin JA; Baumgarten M; DeMichele A; Rubin SC; Berlin M; Troxel AB; Rebbeck TR
Am J Epidemiol; 2006 Oct; 164(8):775-86. PubMed ID: 16997897
[TBL] [Abstract][Full Text] [Related]
20. Use of postmenopausal hormone therapy and risk of Alzheimer's disease in Finland: nationwide case-control study.
Savolainen-Peltonen H; Rahkola-Soisalo P; Hoti F; Vattulainen P; Gissler M; Ylikorkala O; Mikkola TS
BMJ; 2019 Mar; 364():l665. PubMed ID: 30842086
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
